Goldman Sachs sees nearly 140% upside in this biopharma stock

April 20, 2026 7:30 AM

Goldman Sachs initiated coverage of a small-cap biopharma stock with a Buy rating and a price target that implies nearly ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found